Walking a Tightrope: Dosage Modifications and Treatment Outcomes of All-
Journal
JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
entrez:
17
11
2020
pubmed:
18
11
2020
medline:
29
7
2021
Statut:
ppublish
Résumé
The use of all- In this descriptive study, we included 16 out of 28 patients with high-risk APL from two tertiary care centers in South India (Vijayawada and Trichy) between January 2015 and December 2018. A unique approach of initiating ATRA at a dose of 25 mg/m All patients who survived the first 3 days of admission achieved complete remission after a median duration of 29 days. There were no deaths during induction or consolidation, and the regimen was well tolerated; two patients developed grade 3/4 peripheral neuropathy requiring treatment modification. After a median follow-up duration of 1.9 years, there were no hematologic or molecular relapses. The study sheds light on the modifications made to recommended dosages of ATRA, ATO, and DNR to optimize outcomes in high-risk APL and reaffirms the importance of ATO use in the front-line setting to achieve durable responses with minimal toxicity.
Identifiants
pubmed: 33201743
doi: 10.1200/GO.20.00226
pmc: PMC7713580
doi:
Substances chimiques
Tretinoin
5688UTC01R
Arsenic Trioxide
S7V92P67HO
Daunorubicin
ZS7284E0ZP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1749-1756Déclaration de conflit d'intérêts
Conflicts of Interest Statement:
Références
Br J Haematol. 1976 Aug;33(4):451-8
pubmed: 188440
Hematology Am Soc Hematol Educ Program. 2006;:162-8
pubmed: 17124056
Lancet Haematol. 2015 Sep;2(9):e357-66
pubmed: 26685769
Acta Haematol. 2009;121(1):1-8
pubmed: 19246888
J Basic Clin Pharm. 2016 Dec;8(1):1-3
pubmed: 28104966
Blood. 1999 Aug 15;94(4):1192-200
pubmed: 10438706
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Curr Oncol. 2014 Oct;21(5):234-50
pubmed: 25302032
Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):771-7
pubmed: 26361645
Lancet Oncol. 2015 Oct;16(13):1295-305
pubmed: 26384238
Haematologica. 2007 Jul;92(7):994-5
pubmed: 17606455
Value Health. 2005 Sep-Oct;8(5):521-33
pubmed: 16176491
Blood. 2017 Mar 9;129(10):1275-1283
pubmed: 28003274
Blood. 2002 Dec 15;100(13):4298-302
pubmed: 12393590
N Engl J Med. 2013 Jul 11;369(2):111-21
pubmed: 23841729
Blood. 2019 Apr 11;133(15):1630-1643
pubmed: 30803991
Ann Hematol. 2015 Aug;94(8):1347-56
pubmed: 25975975
Haematologica. 2010 May;95(5):853-4
pubmed: 20015875
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35
pubmed: 15044693
Blood. 2011 May 5;117(18):4716-25
pubmed: 21385856
Blood. 2004 Feb 15;103(4):1237-43
pubmed: 14576047
Blood. 2010 Oct 28;116(17):3171-9
pubmed: 20644121
Blood. 2010 Nov 11;116(19):3751-7
pubmed: 20705755
Blood. 2010 Mar 4;115(9):1690-6
pubmed: 20018913
Haematologica. 2007 Oct;92(10):1431-2
pubmed: 18024380
Blood. 2000 Aug 15;96(4):1247-53
pubmed: 10942364
Haematologica. 2007 Mar;92(3):323-31
pubmed: 17339181
Blood. 2010 Jun 24;115(25):5137-46
pubmed: 20393132
J Clin Oncol. 2001 Sep 15;19(18):3852-60
pubmed: 11559723
Expert Rev Hematol. 2011 Aug;4(4):427-36
pubmed: 21801134
Blood. 1997 May 1;89(9):3345-53
pubmed: 9129041